NASDAQ : OKUR
OnKure Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.62 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 106.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 15.19M | 14.69M | 10.37M | 4.82M | 3.90M |
| Research & Development | 46.95M | 48.26M | 43.17M | 32.12M | 25.86M |
| Operating Expenses | 62.14M | 62.95M | 53.54M | 36.93M | 29.77M |
| Operating Income | -62.14M | -62.95M | -53.54M | -36.93M | -29.77M |
| Interest Expense | -8.00K | -8.00K | -148.00K | ||
| Interest & Investment Income | 3.44M | 3.44M | 2.01M | 1.62M | 254.00K |
| Other Non Operating Income (Expenses) | -38.00K | ||||
| EBT Excluding Unusual Items | -58.70M | -59.52M | -51.71M | -35.31M | -29.51M |
| Merger & Restructuring Charges | -225.00K | ||||
| Other Unusual Items | -736.00K | ||||
| Pretax Income | -58.70M | -59.52M | -52.67M | -35.31M | -29.51M |
| Net Income | -58.70M | -59.52M | -52.67M | -35.31M | -29.51M |
| Net Income to Common | -58.70M | -59.52M | -52.67M | -35.31M | -29.51M |
| Shares Outstanding (Basic) | 22.72M | 13.52M | 3.45M | 283.82K | |
| Shares Outstanding (Diluted) | 22.72M | 13.52M | 3.45M | 283.82K | |
| EPS (Basic) | -2.58 | -4.40 | -15.28 | -124.41 | |
| EPS (Diluted) | -2.58 | -4.40 | -15.28 | -124.41 | |
| Free Cash Flow | -47.86M | -51.87M | -51.17M | -34.79M | -28.09M |
| Free Cash Flow Per Share | -2.11 | -3.84 | -14.84 | -122.59 | |
| EBITDA | -61.74M | -62.50M | -53.08M | -36.52M | -29.54M |
| D&A For EBITDA | 403.00K | 447.00K | 459.00K | 417.00K | 229.00K |
| EBIT | -62.14M | -62.95M | -53.54M | -36.93M | -29.77M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 166.50M | 59.05M | 110.76M | 29.88M | 11.54M |
| Cash & Short-Term Investments | 176.39M | 59.05M | 110.76M | 29.88M | 11.54M |
| Prepaid Expenses | 1.29M | 1.79M | 2.24M | 3.89M | 2.08M |
| Total Current Assets | 177.68M | 60.84M | 113.00M | 33.77M | 13.62M |
| Property, Plant & Equipment | 1.27M | 1.00M | 1.79M | 1.91M | 2.05M |
| Other Long-Term Assets | 401.00K | 273.00K | 109.00K | 58.00K | 329.00K |
| Total Assets | 179.35M | 62.12M | 114.91M | 35.73M | 16.00M |
| Accounts Payable | 2.00M | 1.43M | 2.97M | 3.42M | 2.52M |
| Accrued Expenses | 4.31M | 3.94M | 7.03M | 3.66M | 2.87M |
| Current Portion of Leases | 336.00K | 549.00K | 536.00K | 208.00K | 151.00K |
| Total Current Liabilities | 6.64M | 5.92M | 10.53M | 7.29M | 5.54M |
| Long-Term Leases | 590.00K | 549.00K | 466.00K | 486.00K | |
| Other Long-Term Liabilities | 12.00K | 12.00K | |||
| Total Liabilities | 7.25M | 5.93M | 11.08M | 7.75M | 6.03M |
| Common Stock | 4.00K | 1.00K | 1.00K | 1.00K | |
| Additional Paid-In Capital | 416.86M | 270.42M | 258.55M | 209.00K | 2.65M |
| Retained Earnings | -244.74M | -214.24M | -154.72M | -102.05M | -57.07M |
| Total Common Equity | 172.11M | 56.18M | 103.83M | -101.84M | -54.42M |
| Shareholders' Equity | 172.11M | 56.18M | 103.83M | 27.98M | 9.97M |
| Total Liabilities & Equity | 179.35M | 62.12M | 114.91M | 35.73M | 16.00M |
| Total Debt | 926.00K | 549.00K | 1.08M | 674.00K | 637.00K |
| Net Cash (Debt) | 175.46M | 58.50M | 109.68M | 29.20M | 10.91M |
| Net Cash Per Share | 7.72 | 4.33 | 31.82 | 102.89 | |
| Filing Date Shares Outstanding | 40.50M | 13.67M | 13.44M | 13.34M | |
| Total Common Shares Outstanding | 40.50M | 13.67M | 13.35M | 13.34M | |
| Working Capital | 171.03M | 54.92M | 102.47M | 26.48M | 8.08M |
| Book Value Per Share | 4.25 | 4.11 | 7.78 | -7.63 | |
| Tangible Book Value | 172.11M | 56.18M | 103.83M | -101.84M | -54.42M |
| Tangible Book Value Per Share | 4.25 | 4.11 | 7.78 | -7.63 | |
| Machinery | 992.00K | 989.00K | 1.05M | 1.01M | 848.00K |
| Leasehold Improvements | 1.09M | 1.09M | 1.09M | 1.09M | 1.00M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -58.70M | -59.52M | -52.67M | -35.31M | -29.51M |
| Depreciation & Amortization | 797.00K | 830.00K | 662.00K | 560.00K | 387.00K |
| Other Amortization | 142.00K | ||||
| Loss (Gain) From Sale of Assets | 6.00K | 6.00K | |||
| Loss (Gain) From Sale of Investments | -30.00K | 54.00K | |||
| Stock-Based Compensation | 11.81M | 11.63M | 4.53M | 199.00K | 48.00K |
| Other Operating Activities | 120.00K | ||||
| Change in Accounts Payable | -742.00K | -4.54M | -5.93M | 1.71M | 2.65M |
| Change in Other Net Operating Assets | -976.00K | -235.00K | 1.98M | -1.71M | -526.00K |
| Operating Cash Flow | -47.84M | -51.83M | -51.12M | -34.55M | -26.95M |
| Capital Expenditures | -23.00K | -46.00K | -52.00K | -246.00K | -1.13M |
| Investment in Securities | -9.87M | 15.93M | |||
| Investing Cash Flow | -9.89M | -46.00K | 15.87M | -246.00K | -1.13M |
| Long-Term Debt Issued | 6.00M | ||||
| Net Debt Issued (Repaid) | 6.00M | ||||
| Issuance of Common Stock | 150.44M | 240.00K | 58.91M | 65.00K | 340.00K |
| Other Financing Activities | -9.58M | -77.00K | 51.22M | -723.00K | -1.38M |
| Financing Cash Flow | 140.86M | 163.00K | 116.13M | 53.12M | 26.46M |
| Net Cash Flow | 83.13M | -51.71M | 80.89M | 18.33M | -1.62M |
| Free Cash Flow | -47.86M | -51.87M | -51.17M | -34.79M | -28.09M |
| Free Cash Flow Per Share | -2.11 | -3.84 | -14.84 | -122.59 | |
| Levered Free Cash Flow | -27.11M | -31.10M | -23.71M | -22.69M | |
| Unlevered Free Cash Flow | -27.10M | -31.10M | -23.76M | -22.69M | |
| Change in Working Capital | -1.72M | -4.78M | -3.95M | 6.00K | 2.12M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 104.89M | 39.29M | 114.72M | ||
| Enterprise Value | -70.57M | -30.35M | 243.09M | ||
| Last Close Price | 2.62 | 2.90 | 8.60 | ||
| PB Ratio | 0.62 | 0.70 | 1.10 | ||
| P/TBV Ratio | 0.62 | 0.70 | 1.10 | ||
| Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.06 |
| Net Debt / Equity Ratio | -1.02 | -1.04 | -1.06 | -1.04 | -1.09 |
| Net Debt / EBITDA Ratio | 2.84 | 0.94 | 2.07 | 0.80 | 0.37 |
| Net Debt / FCF Ratio | 3.67 | 1.13 | 2.14 | 0.84 | 0.39 |
| Quick Ratio | 26.55 | 9.97 | 10.52 | 4.10 | 2.08 |
| Current Ratio | 26.75 | 10.28 | 10.73 | 4.63 | 2.46 |
| Return on Equity (ROE) | -46.91% | -74.39% | -79.92% | -186.07% | |
| Return on Assets (ROA) | -29.27% | -44.45% | -44.43% | -89.24% | |
| Return on Capital Employed (ROCE) | -36.00% | -112.00% | -51.30% | -129.80% | -284.70% |
| Earnings Yield | -99.77% | -151.48% | -45.91% | ||
| FCF Yield | -45.11% | -132.03% | -44.60% | ||
| Buyback Yield / Dilution | -126.66% | -292.10% | -1,114.54% |